Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia

NCT04311515 is registered in ClinicalTrials.gov with Samus Therapeutics, Inc. as lead sponsor.

NCT NCT04311515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04311515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia
Lead sponsor
Samus Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2020
Completion date
November 15, 2022
Enrollment
4 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease